Welcome to BioNTech's Second Quarter 2023 Update Call. I would like to hand the call over to Dr. Victoria Meissner, Vice President of Strategy and Investor Relations. Please go ahead..

Thank you. Good morning and afternoon. Thank you for joining us today for BioNTech's second quarter 2023 earnings call. As a brief reminder, the slides to accompany this call and the second quarter 2023 press release that was issued this morning can be found in the Investors section of our website.

As outlined on Slide 2, you can see all our forward-looking statements disclaimer. Additional information about the statements and other risks are described in our filings made with the U.S. Securities and Exchange Commission. Forward-looking statements in the call are subject to substantial risks and uncertainties.

We speak only as of the call's original date and we undertake no obligation to update or revise any of these statements. On Slide 3, you can find the agenda for today's call.

Today, I'm joined by the following members of BioNTech's management team, our CEO and Co-Founder, Ugur Sahin, Ozlem Tureci, our Chief Medical Officer and Co-Founder; Jens Holstein, our Chief Financial Officer; and Ryan Richardson, our Chief Strategy Officer. I would like to turn the call over to Ugur Sahin..

antibody, linker, payload. Each of these components has an impact on ADC's pharmacological and clinical properties. It is a precision medicine, allowing for targeted drug delivery, particularly to tumor cells with high specificity and potently induce cell death with the benefit of reduced off-target events.

And the monoclonal antibody binds to the target expressed on the tumor cell. The ADC is internalized allowing for the release of the cytotoxins which leads to cell death.

We continue to broaden our access to ADCs because we believe this technology has the potential to replace highly toxic chemotherapy regimens to become a new combination backbone for cancer immunotherapy. Advancements in this technology have resulted in its extended use for the treatment of solid tumors.

ADCs can also synergize with various immunotherapy modalities including those in our current immunotherapy pipeline. Our growing ADC pipeline now includes ADCs directed against three distinct targets and is of interest for a broad range of cancer types.

In the future, we plan to combine these ADCs with our appropriate pipeline programs to maximize the patient impact of this exciting modality. With that, I would like to thank you all for your confidence in our success and your continued support. I will now turn the call over to Ozlem..

Thank you, Ugur. I'm delighted to speak with everyone today and to provide our pipeline update. Slide 11. Starting with our COVID-19 vaccine.

We expect that as Sars-Cov-2 continues to evolve and the risk of severe COVID-19 disease and death continues, there will be persisting demand for vaccine boosting and vaccinations, especially for at-risk and immunocompromised groups.

So Omicron XBB sub-lineages currently account for the majority of COVID-19 case globally and are energetically distant from prior circulating SARS-CoV-2 lineages, including Omicron BA 4, 5, and the original SARS-CoV-2 strain.

Although, Omicron BA 4, 5 adapted bivalent vaccines provide some protection against a range of outcomes from XBB related COVID-19. Evidence suggests that vaccine better matched to currently circulating sub-lineages can have further improved protection against symptomatic disease and severe COVID-19.

XBB lineage viruses have reduced neutralization in comparison to earlier Omicron lineages but have similar neutralization profiles to each other. Despite sequence of XBB.1.5 and XBB.1.16 differ in only two mutations highlighted here.

In May, the EMA and other health authorities provided guidance highlighting that updated vaccines targeting Omicron XBB.1 sub-lineages may help to maintain protection against COVID-19 during the upcoming fall and winter season, when COVID-19 case rates and hospitalizations are expected to increase.

Also the FDA's Vaccines and Related Biologicals Products Advisory Committee, the VRBPAC, issued guidance recommending manufacture of an Omicron XBB.1.5 adapted monovalent COVID-19 vaccine for the 2023 and 2024 fall and winter seasons.

We and Pfizer submitted regulatory applications to EMT and to the FDA for our Omicron XBB.1.5 adapted monovalent COVID-19 vaccine for individuals six months of age and order.

Following guidance from regulatory authorities on the requirements for strain changes, the applications include data suggesting that Omicron XBB.1.5 adapted monovalent COVID-19 vaccine may generate improved responses against circulating XBB sub-lineages compared to the current Omicron BA.4-5 adapted bivalent COVID-19 vaccine.

Moving to Slide 12, we and our partner Pfizer tested potential effectiveness of an Omicron XBB.1.5 adapted monovalent vaccine as a primary series and booster in mice. Here you see the neutralizing antibody response in mice immunized with our Omicron BA.4-5 adapted bivalent vaccine as booster after two doses of the original vaccine.

One group of mice again received BA.4-5 adapted bivalent COVID-19 vaccine as a fourth dose. And the other group received the new XBB.1.5 adapted monovalent COVID-19 vaccine as a fourth dose.

You can see a four to five-fold increase of neutralization of several XBB related variants when dose four is XBB.1.5 adapted monovalent vaccine as compared to last season's bivalent vaccine, indicating that the XBB.1.5 variant adapted monovalent vaccine in the pre-vaccinated setting has the potential to induce broad cross-neutralizing antibody titers against multiple XBB sub-lineages.

We made significant progress towards monovalent COVID-19 vaccine against Omicron XBB.1.5, with regulatory submissions to the US-FDA, EMA, and other regulatory authorities and we are well-prepared to launch an adapted COVID-19 vaccine if approved in early fall this year. Moving to our oncology pipeline.

Let me put our second quarter pipeline advancements into the broader context of our clinical stage pipeline, which is depicted on Slide 13. In the second quarter, the initiation of our pivotal Phase 3 trial in non-small cell lung cancer marks the first landmark in our strategic collaboration with OncoC4.

The randomized Phase 3 trial is evaluating BNT316 the pH sensitive, anti-CTLA4 antibody with distinctive mode of action and is expected to enroll approximately 600 patients with metastatic immunotherapy resistant non-small cell lung cancer.

The trial initiation follows for FDA Fast-Track designation granted in 2022 and is based on Phase 1/2 safety and efficacy data for the monotherapy in metastatic immune checkpoint inhibitor, resistant non-small cell lung cancer. Further, we expanded our collaboration with Duality and added a third ADC to our oncology pipeline.

DB-1305 is currently in a Phase 1/2 clinical trial for solid tumors. Then I have news from BNT116, our lung cancer antigen based FixVac candidate. The second trial with BNT116 has dosed its first patient end of July.

Together with our partner Regeneron, we will evaluate BNT116 in combination with cemiplimab for the cemiplimab monotherapy alone in treatment naive patients with stage 3b, stage 3c, or stage 4 squamous on non-squamous non-small cell lung cancer patients with at least 50% PD-L1 expression in a randomized multi-center open-label Phase-2 study.

The Phase 1 clinical trial is ongoing with BNT116 to evaluate the safety, tolerability and preliminary efficacy of BNT116 alone and in combination with cemiplimab in patients who have progressed on prior PD-1 inhibitor treatment or are not eligible for chemotherapy and in combination with docetaxel in patients who have received prior PD-1 inhibitor therapy and platinum-based chemotherapy.

We are planning to start several trials with our partners, imminently. Firstly, building on compelling Phase 1 data in patients with resectable PDAC in the adjuvant setting that we recently reported in Nature.

The Phase 2 trial with autogene cevumeran, BNT122, our individualized cancer vaccine candidate is planned with our partner Genentech, evaluating the efficacy and safety of autogene cevumeran in combination with atezolizumab and modified FOLFIRINOX compared to modified FOLFIRINOX as standard of care alone.

Second, another trial is planned to start with our second ADC developed by Duality Bio. BNT324 is a humanized antibody conjugated to a novel DNA topoisomerase-1 inhibitor via a cleavable linker. The Phase 1 part of the study will evaluate the safety in all comers and determine the recommended Phase 2 dose.

In the Phase 2 dose expansion part, we aim to evaluate safety and efficacy in small cell and non-small cell lung cancer, esophageal cancer, prostate cancer, melanoma and other solid tumors. On the next couple of slides, I want to summarize the recently presented data from three of our programs at the ASCO Annual Meeting.

On Slide 14, starting with BNT316/ONC-392 antibody targeting of CTLA4 works primarily by depleting regulatory T-cells and thus their suppression of tumor-specific immunity. Physiologically, CTLA4 recycles continuously between the cell surface and the endosomes.

Interruption of this process by a binding antibody is associated with the development of autoimmunity. Autoimmunity and immune-related adverse events are a major limitation of approved anti-CTLA4 antibodies that disrupt CTLA4 recycling by promoting lysosomal degradation of this important immune checkpoint molecule.

BNT316 in contrast dissociates from the CTLA4 molecule in the endosomes allows normal recycling of both the antibody and the CTLA4 molecule and thus is designed for stronger cancer therapeutic effect and less immune-related adverse effects. Preliminary data showed that BNT316 is well-tolerated with no dose limiting toxicities.

The single agent recommended Phase 2 dose was determined to be 10mg/kg without MTD being reached. Severe immune-related grade 3 adverse event rate in the combo dose escalation with pembrolizumab was 23%, which is considered lower than what was reported for comparable IO-IO combinations. The recommended Phase 2 dose for combination is 6mg/kg.

Overall, BNT316 dosed as monotherapy and in combination was well-tolerated and the safety profile appears to allow higher dosing for a longer duration of treatment as compared, for example, to ipilimumab.

Early efficacy data is monotherapy and platinum resistant ovarian cancer patients and in combination with pembrolizumab in multiple solid tumors were promising.

Slide 15, with our colleagues from OncoC4, we presented data from the Phase 1/2 study investigating BNT316 in 35 non-small cell lung cancer patients with metastatic lesion that progressed on immune checkpoint inhibition in previous slides. The majority of patients had an ECOG status of 1.

The objective response rate was about 30% and disease control rate was 70%. Patients that responded to BNT316 had previously failed multiple lines of treatment, including several immune checkpoint inhibitors. In this cohort, BNT316 has shown managable safety and tolerability when dosed at 10mg/kg twice and followed with 6 mg/kg every three weeks.

Immune related adverse events of Grade 3, 4 were observed in 34% of patients and included immune mediated colitis, ALT/AST increase, and immune hepatitis. Our findings support the further development of BNT316 in non-small cell lung cancer in the Phase 3 study PRESERVE 003.

Slide 16, our second presentation at ASCO was together with our colleagues from Duality Bio and about our first clinical data for our BNT323, our next generation HER2 targeting ADC. BNT323 is comprised of HER2-targeting antibody covalently linked to the proprietary DNA topoisomerase-1 inhibitor via a cleavable linker.

Approved ADCs have shown anti-tumor activity and clinical benefits in multiple types of cancer and we believe that mid-term ADCs as a modality will become a broadly used backbone for combos in oncology. More efficacious and safer anti HER2 ADCs, for example, regarding potential lung toxicity may add further clinical benefit.

Preclinical data for BNT323 distracted significantly improved therapeutic window as compared to DS-8201A or T-DM1 analogs to approved HER2 ADC trastuzumab deruxtecan and trastuzumab emtansine, respectively. BNT323 has a high drug-to-antibody ratio. And when incubated with rat, monkey, and human plasma demonstrated outstanding plasma stability.

In HER2 positive and HER2 negative mixed cell cultures, BNT323 inhibited the proliferation of both cell types, demonstrating its bystander effect. Pharmacokinetic and pharmacodynamic analysis of BNT323 in xenografted mouse models showed targeted delivery of the toxin into tumor tissue.

In vivo studies in monkeys showed a superior stability of BNT323 and rapid systemic clearance of the toxin. Altogether, these properties result in maintenance of efficacy and reduction of systemic toxicity in animal models. Slide 17, the program has received Fast-Track designation from the FDA and is being evaluated in a Phase 1/2 clinical trial.

The study is enrolling pretreated patients with advanced or metastatic HER2 targetable solid tumors. HER2 status is identified via IHC or ISH for expression level via NGS for HER2 amplification or HER2 mutation. The majority of patients had a HER2 expression by IHC of 2+ or 3+.

We showed preliminary anti-tumor activity in heavily pretreated HER2 expressing patients with a median of seven prior systemic treatments, including other anti HER2 ADCs, anti-HER2 antibody therapy, and anti-HER2 TKI therapy. In HER2 positive breast cancer patients, the objective response rate is 50%, the disease control rate is 96%.

In HER2 low breast cancer patients, objective response rate is 38%, the disease control rate is 84%. Anti-tumor activity of BNT323 was also observed in non-breast cancer tumor types such as colorectal cancer, ovarian cancer and endometrial cancer. Responses were observed in-patients treated with different dose levels and HER2 expression status.

BNT323 was well-tolerated and all adverse events were manageable so far. Interstitial lung disease of Grade 1 occurred in two patients out of 85 patients. Expansion cohorts are ongoing in selected tumor patients treated at recombinant Phase 2 dose and we expect further data this year.

Slide 18, finally, we presented data on our cell therapy product candidate BNT211. We developed a highly sensitive second generation CAR targeting CLDN6 with high specificity. The carcino-embryonic antigen CLDN6 is an ideal target for [indiscernible] as it is absent in healthy tissues, but highly expressed in many high medical need cancers.

To improve CAR-T cell engraftment and persistence, we co-developed a CAR-T cell amplifying RNA vaccine of CARVac for short. The goal is to keep CAR-T cells at [indiscernible] particularly relevant.

In animal studies, we have shown that the persistence and effector function of CAR-T cells can be further enhanced by repeated administration of CARVac, a nano-particulate RNA vaccine that encodes Claudin-6.

CARVac is based on our uridine, nucleoside mRNA lipoplex vaccine technology and mediates body-wide RNA delivery to lymphoid compartments resident antigen presenting cells.

In multiple preclinical models, the display of the translated natively folded CAR target protein on antigen presenting cells mediated in-vivo stimulation and controlled expansion of CAR-Ts cells, induced the memory T-cell phenotype, along with higher target sensitivity, and enabled tumor control even if sub-therapeutic CAR-T cell doses were administered.

We are testing the safety, tolerability, and activity of the combination of Claudin-6 CAR-T cells and CARVac in a bifurcated dose escalation study with increasing dose levels of CAR-T cells and the fixed CARVac schedule in patients with various cancer types that occurred in six positive defined as more than 50% of tumor cells with 2+ to 3+ intensity.

Dose escalation has been completed for CAR-T cells derived from a manual manufacturing process. And we have presented data with highly encouraging signs of clinical activity and manageable safety at various conferences in the past.

Slide 19, a subsequent cohort of 19 patients have been treated with our CAR-T product manufactured with a scalable automated version of the process. No DLTs have been observed so far in Claudin-6 CAR-T cells as well as CARVac were well-tolerated, reflecting the safety profile detected in the first dose escalation levels.

Objective response rate was 41% for our 17 available patients and 75% for eight patients treated at dose level two, namely 1 times 10 to the 8 CAR-T cells. Next to germ cell tumors, which dominated the first-dose escalation, we observed ovarian cancer patients responding. We are expecting an additional data read-out later this year.

Once we have determined the recommended Phase 2 dose for BNT211, we plan to initiate a pivotal trial in germ cell tumors, which has already received Prime Designation by the EMA. Advancing our pipeline remains a key strategic priority for the year.

This and next year, we plan to transform our pipeline as we advance multiple programs towards a pivotal stage. I will now pass the presentation to our CFO, Jens Holstein..

Thank you, Ozlem, and a warm welcome to everyone, who dialed into today's call. Before we go into the financial details for the second quarter and the first half of 2023, I'll start with giving you an overview on some key financial figures, which you can find on the next slide.

Our total revenues reached EUR1.4 billion for the first half of 2023 and are in line with our expectations, with Q2 being the expected weakest quarter in the year. Our COVID-19 vaccine revenues are as stated and expected before, heavily influenced by seasonal effects, especially now as we have summer in our biggest markets in the Northern Hemisphere.

As we have outlined in earlier earnings calls, the revenue development for COVID-19 vaccines is expected to mimic a flu-like setting.

I will go into more details concerning our financial guidance in the course of the call, but want to emphasize already now that acknowledging the uncertainties related to the seasonal effect, we reiterate our 2023 COVID-19 vaccine revenue guidance of around EUR5 billion for the full 2023 financial year.

With EUR1.4 billion in revenues, we ended the first six months of 2023, with an operating result of EUR91.1 million and generated earnings per share on a fully diluted basis of EUR1.28.

With respect to the company's financial position, we ended the second quarter of 2023 with EUR16.8 billion, comprising approximately EUR14.2 billion cash and cash equivalents as well as approximately EUR2.7 billion partly current and non-current security investments, which are part of our investment strategy.

Subsequent to the end of the quarter in July 2023, we received EUR1.1 billion in cash from our collaboration partner Pfizer settling our gross profit share for the first quarter of 2023, alongside with EUR0.4 million received until early August in connection with the amendment COVID-19 vaccine Purchase Agreement with the European Commission.

In connection with our acquisition of InstaDeep, which closed on July 31, approximately EUR450 million were invested in form of cash and shares, not including potential future milestones.

Overall, with this strong cash position in the background, we are on track to launch our new variant adapted COVID-19 vaccine and intend to start multiple clinical trials across oncology and infectious disease pipeline, such as the ones with OncoC4 and Duality Biologics that Ugur just mentioned earlier.

I'll be moving to our financial results for the second quarter of 2023 as shown on the next slide. Our total revenues reported reached EUR166.4 million for the second quarter compared to EUR3.2 billion for the comparative prior year period and decreased with the corresponding lower COVID-19 vaccine market demand.

Write-off by our collaboration partner Pfizer, significantly reduced our gross profit share in the second quarter and hence negatively influenced our revenues for the three months ended June 2023.

Let me move to cost of sales, which amounted to EUR162.9 million in the second quarter of 2023 compared to EUR764.6 million for the comparative prior year period. For the first six months of 2023, the cost of sales reached EUR258.9 million compared to EUR2.1 billion for the comparative prior year period.

The changes in line with the decrease in COVID-19 vaccine itself. Research and development expenses reached EUR373.4 million for the second quarter of 2023 compared to EUR399.6 million for the comparative prior year period.

For the first six months of 2023, research and development expenses amounted to EUR707.4 million compared to EUR685.4 million for the comparative prior year period. Our R&D expenses are mainly influenced by progressing clinical studies for pipeline candidates.

The development of variant adapted as well as next generation COVID-19 vaccines and the expansion of our R&D headcount. General and administrative expenses amounted to EUR122.7 million for the second quarter of 2023 compared to EUR130 million for the comparative prior year period.

For the first six months of 2023, G&A expenses reached EUR242.1 million compared to EUR220.8 million for the comparative prior year period. While in Q2, some cost savings have been achieved, G&A expenses for the first six months were mainly influenced by increased expenses for IT services as well as expanding the G&A headcount.

Due to a loss making second quarter of 2023 and the tax effect of a reorganization of the intellectual property rights within the group, income taxes worth an amount of EUR221.8 million were realized compared to tax expenses of EUR647.3 million included for the comparative prior year period.

In total, for the first six months of 2023, income taxes were realized with an amount of EUR16.3 million. Tax income compared to EUR2 billion tax expenses, accrued for the comparative prior year period.

The derived effective income tax rate for the first six months of 2023 were approximately minus 5.5%, which is expected to change over the 2023 financial year to be in line with the updated estimated annual cash effective income tax rate of somewhere around 21% for the BioNTech group, an improvement that I will elaborate on in a minute.

As mentioned at the beginning, due to mainly seasonal effects of our COVID business, we recognized a loss during the second quarter of 2023 amounting to EUR190.4 million, compared to EUR1.7 billion, net profit for the comparative prior year period.

For the first six months of 2023, net profit reached EUR311.8 million compared to EUR5.4 billion for the comparative prior year period. Our loss per share for the second quarter of 2023 amounted to EUR0.79 compared to a diluted earnings per share of EUR6.44 for the comparative prior year period.

For the first six months of 2023, our diluted earnings per share was EUR1.28 compared to EUR20.65 for the comparative prior year period. Now turning to the next slide.

I would like to emphasize that we are updating the company's financial outlook for the 2023 financial year with respect to our planned full year R&D and SG&A expenses as well as our planned expenses and growth and maintenance CapEx for operating activities, excluding effects caused by or driven from in-licensing arrangements, collaborations, or M&A transactions.

Please note that the following numbers reflect current base case projections and are calculated based on constant currency rate and do not include further transactions that could occur in the second half of 2023. As stated before, we reiterate our estimated COVID-19 vaccine revenues of around EUR5 billion for the full 2023 financial year.

Our guidance is based on the expectation that the demand in our vaccine will pick-up in the year's third and fourth quarter along with our rollout of the adapted COVID-19 vaccine against the XBB 1.5. During the second quarter of 2023, the COVID-19 Vaccine Supply Agreement with the European Commission has been amended.

The agreed re-phasing of deliveries annually through 2026 will play an important role in the future as revenues will be recognized over the expenditure. With the EC contract, giving us a level of clarity in terms of revenue expectations, the demand and vaccination rates in other territories as for example, the U.S.

market remain uncertain regarding these metrics. Our collaboration partner Pfizer confirmed its plans to achieve its goals for their markets. Given their detailed plans to support an increase in vaccination rates in the U.S., we expect to achieve our revenue guidance range as previously mentioned.

However, substantial uncertainties underlie the demand for COVID-19 vaccines in general as well as for our vaccine, due to the timing of its approval will have an impact on its demand. There has been no precedent on how COVID-19 vaccine rates will evolve after years of a pandemic where people have been vaccinated multiple times.

We expect to learn from this for future years, but we assume that 2023 will be a very special one, given the mentioned circumstance. It is our aim to move our clinical programs forward as quickly and cost efficiently as possible towards becoming a multi-product company.

To do so, we have implemented further measures to increase cost consciousness, which led to a company-wide cost optimization and hence reduction of our expected 2023 R&D, SG&A spend and capital expenditures.

The increased flexibility at the expenditure level will help us navigate for the just described uncertainties while remaining focused on the development of the next wave of innovation in various fields and indications.

And summarized for you on this slide, we'll update our R&D spending for the rest of 2023 from between EUR2.4 billion and EUR2.6 billion to between EUR2 billion and EUR2.2 billion, including the R&D development costs identified from our latest publicly announced M&A activities.

We also update our SG&A expenses from the EUR650 million to EUR750 million now to between EUR600 million and EUR700 million and reduce our spending for growth and maintenance CapEx for operating activities from between EUR500 million and EUR600 million to between EUR350 million and EUR450 million.

As noted before, we have updated our group estimated annual cash effective income tax rate from around 27% to around 21%, excluding potential effects from share based payment settlement in the course of 2023.

Following a reorganization of the intellectual property rights within the group, we recognize deferred tax effects in Germany and the U.S., previously unrecognized U.S., federal, and state deferred tax assets, including unused tax losses in unused tax credits have been evaluated and now recognized.

The recognition of these deferred tax assets lead to a decrease in the effective tax rate for the fiscal year 2023. And with that, I would now like to turn the call over to our Chief Strategy Officer, Ryan Richardson for an update on our strategic outlook for 2023 and concluding remarks. Thank you..

Thank you, Jens. I'll now provide a brief summary of the commercial outlook for our updated COVID-19 vaccine launch and provide an update on our acquisition of InstaDeep before concluding with our strategic outlook for the remainder of the year and beyond.

I would like to touch on our key readiness activities that have put us in a strong position to execute on our planned launch this fall. On the back of the regulatory recommendation for an XBB.1.5 adapted monovalent vaccine, we and Pfizer have made more than 40 regulatory submissions in key geographies around the world.

We are on track to begin vaccine distribution once regulatory approval is received with first shipments expected from September onwards. We believe Comirnaty is positioned to maintain its leading position in multiple key geographies. Most of the world will continue to be supplied under existing pandemic booster contracts.

This includes our contract with the European Union, our largest contract, which was recently renegotiated to extend to a period over four years. In the United States, we expect our first major commercial market opening where we will leverage Pfizer's commercial capabilities. Turning to the next slide.

This week, we announced that our acquisition of InstaDeep has closed following receipt of all required approvals. With the acquisition we add world-class AI and machine learning technologies and research capabilities to accelerate and enhance our broader strategic vision.

The acquisition will bring over 290 data scientists, ML engineers, and tech professionals to our team, positioning us to lead in this disruptive new field.

And combining InstaDeep's AI and ML expertise with our own research and development capabilities, we aim to develop novel therapeutic and vaccine product candidates with increased speed and efficiency. We also see opportunities to leverage these AI and ML capabilities outside of R&D across other functions of BioNTech.

This makes this a highly strategic acquisition with significant long-term transformational potential across our firm. We will operate InstaDeep as an independent technology subsidiary BioNTech. On the next slide, we show the three pillars of value creation that we expect from this transaction.

The first is to apply cutting-edge AI and machine-learning technologies across our therapeutic and vaccine platforms. We plan to connect these AI-enabled discovery capabilities with automated lab infrastructure to enable high throughput drug discovery.

While we do expect our overall AI investments to increase in the coming years, we do expect some mid-term cost efficiencies from the acquisition by internalizing our largest AI technology and services provider.

Finally, we will continue to operate InstaDeep's third-party business, which delivers technology solutions and services to external customers in the technology sector and other industries.

We are excited to kick off the next phase of our collaboration with the leadership and bright minds at InstaDeep and believe that together we can become a global leader in applying cutting-edge artificial intelligence and machine-learning technologies to discover, design, and develop next-generation immunotherapy at scale.

The next slide provides an overview of our expected pipeline news flow for 2023 and 2024. Some of these points have been covered, so I won't go through them all in detail here. With the collective efforts and dedication from our teams, we've achieved remarkable progress for several of our product candidates.

At this year's ASCO congress, we presented data for three of our pipeline candidates. We're on track to share additional data updates across a range of technologies later this year. In June, we initiated our first Phase 3 trial in oncology.

Additionally, we started the Phase 2 trial for one of our FixVac candidates in collaboration with Regeneron, focusing on first-line NSCLC. As Ozlem has elaborated, we anticipate initiating several further trials in the near future. On the next slide, I'll summarize the strategic outlook for the remainder of the year.

We are on track to roll out our new variant adapted COVID-19 vaccine in the coming month. We also plan to initiate multiple registrational oncology clinical trials while expanding our infectious disease pipeline.

With the InstaDeep acquisition now closed, we intend to rapidly scale up our activity in AI-enabled drug discovery and will continue to execute transactions to expand our innovation ecosystem and execute on our corporate development strategy to in license complementary assets.

Before concluding and opening up the floor for questions, I'd like to reiterate that we will hold our Innovation Series event on November 7. We'll provide further details on the event in the coming weeks. With that, I'd like to thank our shareholders for their continued support, and I'll conclude our prepared remarks and open the floor for questions..

Thank you. [Operator Instructions] We will now go to your first question. One moment please. And your first question comes from the line of Daina Graybosch from Leerink Partners. Please go ahead..

Yeah. Thank you for the question. I have one ONC-392. The Phase 3 that you’ve started, I forgot the name of it, is different is design from the Phase 2 in some of the inclusion, exclusion criteria.

And I wonder if you could talk about why the differences and why you started decided to go forward now in a Phase 3 with single-agent CTLA4 rather than gathering more data and doing a combination study with PD-1 or any other agents in this pretty hard to treat and difficult to do trial setting?.

Daina, hi. It's Ugur. Thank you for the question. So as you know, the Phase1/2 study collected data in different combinations. And they have seen -- we have seen single compound activity in non-small cell lung cancer in patients who had received and progressed under first line checkpoint locate treatment.

They showed encouraging objective response rate around 35%. We do not see an added benefit in combining that with the current status quo, which is chemotherapy and therefore decided in the -- in also this favoring -- a clean safety profile to go with a single compound alone.

And the patient population that have been selected for the study reflects historical patient populations with regard to the inclusion and exclusion criteria..

Ugur, perhaps a follow-up. I think the difference, tell me if I'm wrong, was the length for which the patients could have received the prior checkpoint that it's a lot -- you're requiring a longer prior checkpoint in Phase 3 than you did in the Phase 2.

For some Phase 2 patients wouldn't be eligible for Phase 3, do you expect any negative impact from….

Daina, the protocol has also emerged based on decision with the FDA and FDA request..

Got it. Thanks..

Thank you. We will now go to your next question. And your next question comes from the line of Tazeen Ahmad from Bank of America. Please go ahead..

Hi. Good morning and thanks so much for taking my question.

Just a point of clarification, as you think about the rest of the year for COVID vaccine sales, I know you talked about the difficulties involved in really getting a sense for the trends, but when you decided to maintain guidance, at least for now, what key factors are you taking into account that gives you confidence that sales will be or revenues rather will be at least close to, if not at the EUR5 billion mark.

And I think that's probably the best question for Ryan to answer. Thanks..

Yeah, I'll start, Tazeen and then Jens should also chime in here. So, I think the starting point here was that we are expecting the total volume of COVID vaccines in the fall to be down. You may remember that last year we had distributed more than 500 million doses of our B4, B5 variant adapted vaccine globally.

And for the full year, last year, we had -- the market in United States was about 144 million doses. We are expecting those numbers to come down both in the United States and globally. So we factor that in. However, we also expect that in the United States that we're going to see a commercial market opening, so a higher price point.

So we along with Pfizer have talked about a gross price in the $110 to $130 range. That's our expectation. And so, higher price point in the U.S.

and much of the rest of the world, we're still expecting contracts that have already been signed to be the primary sort of contractual mode governing the second half of deliveries, but demand will still matter. So in the rest of the world, we're still expecting effectively continuation of the booster contracts and that's factored in as well..

Yeah. Maybe, Tazeen, just to add. I mean, Ryan basically describes the situation. And I think we've made some statements in our speeches as well in that respect, that of course the situation like we currently see hasn't been seen before for any product so far. Patients have received -- people have received multiple vaccinations in the last two years.

And of course, there is some level of tiredness so to stay on getting vaccinated. But we see the need for further vaccinations.

And I think specifically for the U.S., you've heard probably some of the plans that Pfizer and as well as our competitor Moderna has announced on how the expectations will be going up for the rest of the year to pick up with the vaccination rates.

So in that respect, the next couple of months, the next two, three months will give us a good sign how the year will end. There is some uncertainty we just wanted to make that clear. And we see 2023 is a very special year, though too. I have to say so.

From our perspective, that situation that people have received multiple vaccinations and now are maybe a little bit tired has to grow into a market where you have annual vaccinations.

And I think it gives -- '23 gives us some indication, but we also believe there will be a further increased potential from our perspective for '24 and the other years, just given the specific situation that we now have in this year with two years of multiple vaccinations for people..

Okay. Thank you..

Thank you. We will now go to your next question. And your next question comes from the line of Akash Tewari from Jefferies. Please go ahead..

Hi, everyone. Thanks so much for taking our question. This is Amy on for Akash. So Pfizer has alluded to an enterprise wide cost cutting program, particularly around COVID its long-term vaccine demand ends up being modest.

How would Pfizer's cost cut change your long-term OpEx on your COVID programs and spend more broadly? And on a related note, can you go over what's changed in your new 2023 OpEx and CapEx guide? We're seeing that BNT141 isn't on your pipeline slate this quarter. Are there any other components that may be driving these cost cuts? Thanks so much..

Yeah. Thank you for the questions. So I'll speak to the OpEx point and then I'll ask Jens to opine on what's driving the cost lines in our guidance. But on the OpEx side, the short answer is no. And actually one of the unique features of our economic model for COVID-19 is that our OpEx is very lean.

So, as you may recall, we get a gross profit share on every COVID vaccine dose produced and delivered through the Pfizer partnership, and only in Germany and Turkey, we booked topline product sales and actually have significant OpEx, only in those two countries.

So that does translate into a very differentiated profile across our P&L and I think you see some of that lean is reflected in the numbers that we've disclosed today.

Jens, do you want to speak to the drivers of the costs in respect?.

Yeah. I mean, for us, and we of course can only talk for us, and we cannot talk about Pfizer and their cost cutting plan that they have announced in the earnings call. So far, from our perspective, we see a little bit less spend for the collaboration with Pfizer in the course of 2023.

But we also have a close look on our own spending in the areas of oncology, for example, or in building up production capacities. So those have been specific areas where we just look at controlling our costs going forward to have more flexibility..

Great. Thanks so much..

Thank you. We will now take your next question. And the question comes from the line of Chris Shibutani from Goldman Sachs. Please go ahead..

Yeah. Two questions if I can. One on the pipeline and the other more financially related on the pipeline, BNT122 first line metastatic melanoma. It seemed a bit conspicuous in terms of the absence of mentioned in the press release and prepared comments. I do see it in the pipeline table.

Have your expectations for this trial change that we should still be expecting updates in the balance of this year? And then I have a follow up on financial..

Yeah. Thanks, Chris. Let me start on the BNT122 and Ugur and Ozlem can also chime in here. So we've reiterated our guidance for an update later this year. We still intend to provide that. I think on a previous call, we had also mentioned that the PFS analysis would be triggered on an event basis.

And the fact is, we still haven't met that event trigger -- reached that have been trigger -- which does mean that we're not in a position right now to be specific about the full -- the data that we're likely to bring out later this year.

So we do intend to provide an update before year end, but I think it's likely that there won't be a full data update. So more to come on that..

I can just echo what Ryan said, gathering these events has not entirely under our control and therefore, we at this point cannot forecast when we will be able to report the data, interim analysis data point..

Got it. And then on the financial follow up, very healthy cash balance, obviously post COVID. And we are watching the decisions you're making on the capital allocation front. The InstaDeep is an example of that. And Ryan, you mentioned during the call you look to intend to continue to in license assets.

Can you give us a sense for, potentially any areas that you feel either disease area, modality, size, a lot of these have been smaller and InstaDeep was a little bit more kind of adjacent as opposed to immediately obvious. Just be helpful to get a sense for what this mosaic is that you're creating given your capacity..

Yeah. Absolutely, Chris. So as you see from the deals we've announced so far this year that we've allocated a little bit less than $1 billion in terms of upfront payments across the entity transaction and then several in licensing deals for several assets that we've talked about today.

So I think, in that sense, InstaDeep was a sort of strategic exception. We thought that was a very unique opportunity. I wouldn't expect that that would be one that would be replicated as such, but I think the licensing deals and small-scale M&A.

I think, you can expect us to continue to operate along the same lines as what you've seen so far in the first half of the year. So relatively small deals, those are at our sweet spot, under one billion is our sweet spot.

We will look at and consider larger deals, but that's -- I think it has to be a very, very good strategic fit for us to make a larger move. We do see opportunities in that sub $1 billion range to further bolster the pipeline.

And in terms of focus areas, as you've seen so far in the first half, I/O, differentiated I/O assets are going to continue to be an area of focus..

Great. Will look for more insights on your Innovation Day. Thank you..

Thank you..

Thank you. We will now go to the next question. And your next question comes from the line of Yaron Werber from TD Cowen. Please go ahead..

Hi. Thanks very much for taking the question. This is Brendan on for your Yaron. Just really quickly wanted to also ask maybe about the potential flu-COVID combo approach here. First, I guess when you think we might see data from that study but also maybe a little bit more broadly, kind of what the path forward is for the combo.

And really, I guess, trying to understand with each updated booster, how this would kind of play out here, just kind of trying to get at, seeing if you could kind of cast some doubt, a little bit on the whole mRNA approach obviously from your own perspective, but really how you're kind of thinking about mRNA fitting into the whole COVID-flu combo space from what you're seeing at this point.

Thanks..

Yeah. Sure. I'll start. So as you know, Pfizer currently has an ongoing Phase 1 study of a flu-COVID combo vaccine. And they also have a Phase 3 study ongoing of their flu mRNA flu vaccine, which we've licensed the technology to them. We still retain some economics on the program, but they're in control and driving that program, mono program.

So we do see opportunity for a combination vaccine. I think in terms of timelines, Pfizer has guided to a potential Phase 1 data update this year for the combination. And they've also guided in near-term Phase 3 data on the flu mono, both of which I think will be relevant data points here to help inform the next stage of development.

The last point I would add is just that Pfizer has indicated I think just in the last couple of days, but are they have reiterated that they see a flu -- both a flu mono and also flu COVID combo being starting to become relevant from 2024 onwards. So not something to look at this year.

Although, I think positive data could obviously be a helpful catalyst for us as well..

Thank you. We will now go to our next question. One moment, please. And your next question comes from the line of Terence Flynn from Morgan Stanley. Please go ahead..

Great. Good morning and thanks for taking the question. Just I was wondering, if you could elaborate more on the rationale to advance BNT116 into the metastatic setting. Well, in iNeST I know you've talked more about the potential there in adjuvant settings. So just wondering if you could kind of compare and contrast those two approaches. Thank you..

Yeah. Thank you. The question is highly relevant. It's -- FixVac approach is based on the off the shelf availability of the vaccines, that means, in the metastatic setting, the disease is rapidly progressing.

We would like to get as quickly as possible, an immune response initiated and personalized vaccine in the vaccine approach requires around four to six weeks for preparations of the vaccine and is particularly suited for the adjuvant setting. And because in the adjuvant setting, there is a longer time frame before patients progress.

So that gives us opportunity to build an immune response that can counter a potential progression of disease. Therefore, all the adjuvant ties, they have as an endpoint relapse free survival as an endpoint, whereas as in the metastatic setting endpoints will be, for example, progression free survival, OOS..

Thank you. We will now go to our next question. And your next question comes from the line of Bill Maughan from Canaccord. Please go ahead..

Hi. Thank you. So I have a question on self-amplifying RNA. I know that you had to been developing a few programs with your self-amplifying RNA and it's kind of not center stage anymore, but several other companies that are earlier in their cancer vaccine development are using self-amplifying RNA and kind of singing its praises.

So I was just wondering if we could expect self-amplifying RNA to occupy some more of the spotlight and maybe be advanced in some programs coming up in the future. Thanks..

Yeah. Thank you for the question. As you know, we have two mRNA amplification program self-amplifying mRNA program as well as the amplification program.

We have observed and if you look closer into the data into public data of we have observed that the self-amplifying mRNA in humans are limited in the full response on innate -- quick initiation of innate response and hindering the full capacity of self-amplifying mRNA.

And we are working on an improved approach of overcoming this innate immune response limitation on a adapted monovalent amplifying mRNA platform, which combines two advantages, the advantage of safety. So the itself is not amplified. It provides only mRNA activity and the target mRNAs are amplified.

We thereby separate target mRNA in the replicate mRNA and have the opportunity to combine multiple targets.

And this is something where we made a lot of progress in the preclinical setting, and we will report end of this year here on this platform, particularly we see here suitability in the infectious disease setting, particularly in the setting of combination vaccine..

Thank you..

Thank you. We will now go to the next question. And your next question comes from the line of Ellie Merle from UBS. Please go ahead..

Hi guys, this is Sarah on for Ellie so much for taking our question. I guess a quick one on 211 and the data update later this year. It's what are the expectations for data and what are you guys hoping to see? Thanks..

Thank you for the question. So we have an ongoing Phase I/II trial, and we have had a couple of data updates this year, the year before.

And the trial is ongoing what we expect to report end of this year is additional data on the one hand, on safety of different doses and in combination with our CARVac vaccine, also data on clinical activity in additional clinical indications. We have been very focused on testicular cancer in the previous updates.

Further, we will report on durability of these responses. We have been focused on objective response rates. Now that the data is maturing, we will provide more insights into durability of those responses and how use of a vaccine impacts that..

Thank you..

Thank you. Thank you. We will now take our last question for today. And your last question comes from the line of Simon Baker from Redburn. Please go ahead..

Thank you for taking my question. It relates to the PRESERVE-003 study. It's a 2-stage Phase III study.

So I just wanted to get some idea of what data you will be presenting at the conclusion of Stage 1 and any timing that is indicated based on your expectations for and recruitment? And I see the clinical trials is showing a primary completion in mid-2026.

Is that a reasonable estimate at this stage for the final data of Stage 2?.

I didn't fully get that, Simon.

Was this about data expectations for the ongoing ONC392 trial?.

Yes, it was because it's a 2-stage study.

So I wondered what data you will disclose when Stage I is completed and the dose is selected?.

So it will be safety data and clinical activity data in different tumor indications..

I think it's a lung cancer trial..

Sorry, I didn't get that..

So we expect around 2025 data and safety data. Now we have started the clinical trial with two different doses. We will select one dose to continue. And it's a stage approach based on the data, initial assessment of the PFS that clinical trial will continue for full maturation..

Great. Thanks so much..

Thank you..

Thank you. This concludes today's conference call. Thank you for participating. You may now disconnect..

Thank you..